Active Biotech Interim Report Q1 2022 : vimarsana.com

FIRST QUARTER IN BRIEF Dr. Erik Vahtola appointed Chief Medical Officer (Jan 01)First patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma (Feb 07)Active

Related Keywords

Hans Kolam , Erik Vahtola , Loncode Institute , Chief Medical Officer , Active , Biotech , Interim , Report , 022 ,